Table 2.

Univariate Comparison of Comorbidities Between FH and Non‐FH Cohort

	FH Cohort		Non‐FH Cohort		P Value
	n	%	n	%
Total	32 613	13.71	205 290	86.29
Hypertension	21 318	65.37	133 137	64.85	0.07
Renal disease	5659	17.35	30 958	15.08	<0.0001
Cancer	5938	18.21	37 488	18.26	0.82
Angina	2446	7.50	7354	3.58	<0.0001
Myocardial infarction	4817	14.77	17 092	8.33	<0.0001
Heart failure	3854	11.82	21 557	10.50	<0.0001
MACEa	9202	28.22	40 832	19.89	<0.0001
Ischemic stroke	2118	6.49	13 044	6.35	0.33
Ventricular arrhythmias	1701	5.22	9710	4.73	0.0001
Percutaneous coronary intervention	3086	9.46	8150	3.97	<0.0001
Coronary artery bypass grafting	2488	7.63	10 427	5.08	<0.0001
Implantable cardioverter defibrillator	577	1.77	2857	1.39	<0.0001

FH indicates familial hypercholesterolemia; MACE, major adverse cardiovascular events.

^aMACE is a composite of death, myocardial infarction, percutaneous coronary interventions, and coronary artery bypass grafting.